How has been the historical performance of Novartis India?

Oct 28 2025 10:56 PM IST
share
Share Via
Novartis India has experienced fluctuating financial performance, with net sales declining from INR 490.68 crore in March 2019 to INR 356.27 crore in March 2025, while operating profit significantly improved from INR 12.28 crore to INR 133.38 crore during the same period, indicating a recovery in profitability despite declining sales. Total assets and liabilities also decreased, reflecting reduced financial obligations.
Answer:
The historical performance of Novartis India shows fluctuations in key financial metrics over the years, with notable trends in net sales, operating profit, and profit after tax.

Breakdown:
Novartis India's net sales have seen a decline from INR 490.68 crore in March 2019 to INR 356.27 crore in March 2025, with a peak of INR 399.87 crore in March 2022. Total operating income followed a similar trend, decreasing from INR 490.68 crore in March 2019 to INR 356.27 crore in March 2025. Operating profit (PBDIT) has improved significantly, rising from INR 12.28 crore in March 2019 to INR 133.38 crore in March 2025, indicating a strong recovery in profitability. Profit before tax also increased from INR 85.77 crore in March 2019 to INR 130.42 crore in March 2025, while profit after tax showed a recovery from a loss of INR 3.72 crore in March 2022 to INR 100.90 crore in March 2025. The company's cash flow from operating activities improved from a negative INR 69 crore in March 2021 to INR 74 crore in March 2025, reflecting better operational efficiency. Total assets decreased from INR 1,052.90 crore in March 2020 to INR 932.33 crore in March 2025, while total liabilities also decreased from INR 1,052.90 crore in March 2020 to INR 932.33 crore in March 2025, indicating a reduction in financial obligations. Overall, Novartis India has shown a recovery in profitability and operational cash flow despite declining sales and total assets.
{{stockdata.stock.stock_name.value}} Live

{{stockdata.stock.price.value}} {{stockdata.stock.price_difference.value}} ({{stockdata.stock.price_percentage.value}}%)

{{stockdata.stock.date.value}} | BSE+NSE Vol: {{stockdata.index_name}} Vol: {{stockdata.stock.bse_nse_vol.value}} ({{stockdata.stock.bse_nse_vol_per.value}}%)


Our weekly and monthly stock recommendations are here
Loading...
{{!sm.blur ? sm.comp_name : ''}}
Industry
{{sm.old_ind_name }}
Market Cap
{{sm.mcapsizerank }}
Date of Entry
{{sm.date }}
Entry Price
Target Price
{{sm.target_price }} ({{sm.performance_target }}%)
Holding Duration
{{sm.target_duration }}
Last 1 Year Return
{{sm.performance_1y}}%
{{sm.comp_name}} price as on {{sm.todays_date}}
{{sm.price_as_on}} ({{sm.performance}}%)
Industry
{{sm.old_ind_name}}
Market Cap
{{sm.mcapsizerank}}
Date of Entry
{{sm.date}}
Entry Price
{{sm.opening_price}}
Last 1 Year Return
{{sm.performance_1y}}%
Related News
Why is Novartis India falling/rising?
Dec 05 2025 12:56 AM IST
share
Share Via
Why is Novartis India falling/rising?
Nov 06 2025 10:05 PM IST
share
Share Via
Is Novartis India overvalued or undervalued?
Nov 05 2025 08:06 AM IST
share
Share Via
Is Novartis India overvalued or undervalued?
Nov 03 2025 08:04 AM IST
share
Share Via
Is Novartis India overvalued or undervalued?
Nov 02 2025 08:04 AM IST
share
Share Via